Product Reports Resources Pricing Login Book a demo

Vascular Graft Solutions

Health Tech & Medtech · Tel Aviv-Yafo, Israel · Founded 2009

Develops innovative solutions to improve the outcome of bypass surgery and patients’ quality of life MoreLess

Vascular Graft Solutions (VGS), established in 2009, focuses on improving coronary revascularization procedures through innovative technologies. Operating in the medical device industry, VGS primarily serves cardiac surgeons and healthcare providers involved in coronary artery bypass grafting (CABG). The company aims to enhance both short and long-term outcomes of CABG, a widely performed cardiac surgery, by providing external support for vein grafts. VGS's business model revolves around the development, clinical validation, and commercialization of its patented devices, which are FDA cleared and CE marked for sale in various regions including the US, Europe, Australia, Israel, and Mexico. Revenue is generated through the sale of these medical devices to hospitals and healthcare facilities. VGS's mission is to advance the standard of care in coronary bypass surgery, focusing on improving patient quality of life and reducing the economic burden on healthcare systems.

Keywords: coronary revascularization, CABG, medical devices, vein graft support, FDA cleared, CE marked, cardiac surgery, healthcare innovation, clinical validation, patented technologies.

Company overview

Vascular Graft Solutions company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2009
Headquarters
Tel Aviv-Yafo, Israel
Employees
18
Open positions
None listed
Dealroom signal
71.7
client focusb2btechnologyDeep Techsub industryMedical Devicesbusiness modelManufacturingindustryHealthsectormedical implantssectorSurgerysectorCardiology and cardiovascularsectorPatient CaresectorSpinoutsectorHospitalsectorDT and LSsectorscience-based

Valuation & funding

Vascular Graft Solutions funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES CEquity / VC May 2024 $12M $48M Undisclosed
SERIES CEquity / VC Jan 2022 $12M $48M Undisclosed
LATE VCEquity / VC Jun 2019 $4M $16M Undisclosed
SERIES BEquity / VC Jun 2018 $0 Champel Capital
SERIES BEquity / VC Feb 2014 $2M $8M Undisclosed
DEBTDebt Feb 2012 Broadview Ventures
GRANTOther financing Jul 2011 Undisclosed
SERIES AEquity / VC Jan 2011 Undisclosed
SPINOUTOther financing Jan 2009 Tel Aviv University
Showing 9 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

YearEmployees
2026 17
2025 17
2024 24
2023 30
2022 28
2021 24
2020 23
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Vascular Graft Solutions website traffic

Latest recorded traffic for Vascular Graft Solutions is 400 monthly website visits, down 57.9% over the last three months. Vascular Graft Solutions's team grew 5.9% over the past year.

Latest monthly visits400 3-month web change-57.9% 1-year team growth+5.9%
Monthly website visits103 observations · Jun 2015–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Vascular Graft Solutions compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Vascular Graft Solutions's talent

Book a demo to see the people
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

8 investors on Vascular Graft Solutions's cap table

Sourced from Dealroom's funding and investor records.

Series A 1 investor entered at this stage
Champel Capital
Series B+ 1 investor entered at this stage
Broadview Ventures
Other known 6 additional known investors
Tel Aviv University
Akilia Partners
Medison Ventures
Pontifax Funds
RAD BioMed
Tal Ventures

Global footprint

Where Vascular Graft Solutions has talent and traffic

Workforce by country
1 countries with
team presence
🇮🇱 Israel45.5%
1 country shown

In the news

Latest news about Vascular Graft Solutions

Recent press, funding announcements, and product moves mentioning Vascular Graft Solutions — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Vascular Graft Solutions

An AI-synthesized read of the highest-engagement posts about Vascular Graft Solutions on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vascular Graft Solutions’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.